IRCT20210110049990N1 IRCT 2021-03-01 Shahid Beheshti University Of Medical Science Evaluation of the effect of melatonin on colistin nephrotoxicity Evaluating the effect of oral melatonin in colistin induced nephrotoxicity in the intensive care unit 2021-03-21 anticipated 40 Complete https://irct.ir/trial/53643 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Using statistical software tools randomized using random numbers to assign a code to each patient by the pharmacotrapist is done with the conceal. The distribution of melatonin to the intervention group and placebo to the control group is done by the ward nurses based on the accident reported by the pharmacotherapist. Researchers and nurses will not be aware of the results of randomization and the type of package they give to patients. The researcher provides the necessary medication for the nurses to perform the intervention, Blinding description: In this double-blind study, the pharmacotherapist performs randomized statistical software using randomized statistical software. The drug and placebo are given a code and key about the drugs is given only to the principal investigator. 2-3 Nephrotoxicity. Intervention 1: Intervention group: Patients receive a treatment protocol approved by the Ministry of Health during their hospital stay. Patients in the intensive care unit treated with colistin will receive one melatonin tablet at a dose of 3 mg per night. Melatonin is a substance that is naturally secreted through the pineal gland and its role is to help the sleep-wake cycle. Intervention 2: Control group: Patients receive a treatment protocol approved by the Ministry of Health during their hospital stay. They will receive a placebo every night for a maximum of ten nights. Yes - There is a plan to make this available What will be shared: In this study, none of the patients' personal information will be shared. Only data that is shared relates to the main consequences of the intervention. When: The access period starts 6 months after the results are published. To whom: The data will be available to researchers at academic and scientific institutions as well as physicians. Conditions: Applicants are only allowed to use the information available to them only in clinical practice and should not publish this information. Where to obtain: Ways of contacting applicants: 1- Contact number: 09181110628 2- E-mail address: p.Shojaei @ sbmu.ac.ir 3- Address: Tehran, Shahid Madani St., Imam Hossein Hospital, Dr. Pouja Shojaei How to obtain: Applicants should receive the necessary information within ten days after making a call to the announced numbers or sending an email. Comments: